Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1201-1220 of 1,743 trials

Trabectedin for HEY1-NOCA2 Positive Mesenchymal Chondrosarcoma

We are studying the effects of trabectedin in adults and young adults with advanced mesenchymal chondrosarcoma who have already received other treatments. The trial aims to assess how well this medication works in reducing tumors and improving patient outcomes.

Mesenchymal Chondrosarcoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Pseudomyxoma Peritonei: Neoadjuvant Chemotherapy Study

We are studying whether a combination of capecitabine and cyclophosphamide can help patients with large Pseudomyxoma peritonei before surgery. The goal is to see if this treatment improves tumor shrinkage and surgical success.

Pseudomyxoma Peritonei>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Acute Myeloid Leukemia: JNJ-90189892 Treatment

We are testing a new medication for patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasms. The study aims to determine the safest dose and gather initial information on its effects.

Relapsed or Refractory Acute Myeloid Leukemia>2 yearsSafety phase (I)HematologyOncology

Burn Patients: Antibiotic Use Before Surgery

We are studying whether giving antibiotics before skin graft surgery helps reduce infections and complications in burn patients. This research may provide insights into improving recovery and hospital stays.

Burn Injury>2 yearsConfirmation phase (III)Standard MedicinesPartially RemoteInfectious DiseasesOrthopedics and Traumatology

PRCA Treatment: Isatuximab Study

We are studying whether the drug isatuximab can help patients with pure red cell aplasia after stem cell transplantation. This trial compares its effects to standard supportive care to see which is more effective.

Pure Red Cell Aplasia>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Idiopathic Retroperitoneal Fibrosis: Early Steroid Discontinuation Study

We are investigating whether stopping steroid treatment early in patients with idiopathic retroperitoneal fibrosis affects relapse rates. This study aims to improve treatment strategies for managing this condition.

Idiopathic Retroperitoneal Fibrosis>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineRheumatology

Systemic Lupus Erythematosus: Cenerimod Study

We are examining the long-term safety and tolerability of cenerimod in adults with systemic lupus erythematosus. This study looks at how the medication works alongside existing treatments.

Systemic Lupus Erythematosus>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Diabetic Macular Edema: Dexamethasone Implant Study

We are investigating a new treatment using a dexamethasone implant for patients with diabetic macular edema. The goal is to see if it improves vision and how well patients tolerate the treatment.

Diabetic Macular Oedema>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesEndocrinologyOphthalmology

Candidiasis Treatment: Mecloderm® Cream Study

We are comparing a new cream to standard treatments and a placebo for patients with moderate to severe skin candidiasis. The goal is to see which option works best for reducing inflammation and discomfort.

Skin and Nail Candidiasis>2 yearsConfirmation phase (III)Dermatology

Short-Term Insomnia: Neurexan® Treatment

We are exploring whether Neurexan® can improve sleep quality and daytime performance in people with short-term insomnia. This study compares its effects to a placebo to understand its potential benefits.

Short-Term Insomnia>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteNeurologyPsychiatry

Neovascular AMD: Faricimab Treatment Study

We are exploring whether two initial doses of faricimab can help keep neovascular AMD inactive in treatment-naive patients. The study also looks at factors that may predict disease activity and recurrence.

Age-related Macular Degeneration>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesOphthalmology

Nivolumab and Entinostat for High-Risk Cancers in Kids

We are exploring a new treatment combining Nivolumab and Entinostat for children and adolescents with hard-to-treat cancers. The study aims to see if this combination can help those with specific tumor characteristics.

Relapsed or Refractory High-Risk Malignant Disease>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyPediatrics

BCG Vaccination: Understanding Immune Response

We are studying how pre-vaccination immune status affects the response to the BCG vaccine. This research may help improve vaccination strategies by identifying key immune factors.

Healthy Participants>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementInfectious Diseases

Ewing's Sarcoma: Naxitamab Treatment Study

We are evaluating the safety and effectiveness of naxitamab added to standard chemotherapy for patients with refractory Ewing's sarcoma. This study aims to see if this combination can improve treatment outcomes.

Ewing's Sarcoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Cognitive Dysfunction in Schizophrenia: Clemastine and Exercise Study

We are investigating whether combining Clemastine with aerobic exercise can improve cognitive function in people with schizophrenia. The study aims to see if this approach enhances memory and overall functioning.

Schizophrenia>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesPsychiatry

AMG 193 for Advanced Non-Small Cell Lung Cancer

We are studying a new treatment, AMG 193, for patients with advanced non-small cell lung cancer that has a specific genetic deletion. The trial aims to evaluate its safety and effectiveness compared to existing options.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

New Treatment for Primary CNS Lymphoma: Optimizing MATRix

We are studying a modified treatment approach for patients with newly diagnosed primary CNS lymphoma to see if it improves survival and quality of life compared to standard therapy. This trial aims to find a safer and effective way to induce remission before further treatment.

Primary Central Nervous System Lymphoma (PCNSL)>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Wart Treatment: 2LVERU® JUNIOR and 2LVERU®

We are studying whether two new treatments can help people with warts get rid of them more effectively than a placebo. The trial will also look at pain levels and safety during treatment.

Warts>2 yearsConfirmation phase (III)Monitoring phase (IV)Standard MedicinesDermatologyInfectious Diseases

Breast Cancer: Shorter Hormone Therapy Duration

We are studying whether limiting hormone therapy to 2 years is effective for women with hormone-sensitive breast cancer at very low risk of recurrence. This trial aims to assess the safety and quality of life during and after treatment.

Localized Luminal A Breast Cancer in Post-Menopausal Women>2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteEndocrinologyOncology

Giant Cell Arteritis and Rheumatoid Arthritis: PET/CT Imaging Study

We are testing a new imaging method to see inflamed arteries in giant cell arteritis and inflamed joints in rheumatoid arthritis. This study aims to improve how we visualize and understand these conditions.

Giant Cell ArteritisRheumatoid Arthritis>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementCardiologyRheumatology